查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601615

微小殘留疾病檢測市場規模、佔有率、預測、趨勢分析：按提供、按技術、按應用、按樣本類型 - 到 2031 年的全球預測

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology (PCR, Flow Cytometry, NGS) Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor) Sample (Blood, Bone Marrow) - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 265 Pages | 商品交期: 最快1-2個工作天內

價格

微小殘留疾病(MRD) 檢測市場規模、佔有率、預測、趨勢分析：提供的服務、技術（PCR、流式細胞儀、NGS）、應用（淋巴瘤、白血病、多發性骨髓瘤、實體瘤）、樣本（血液、骨髓） - 到 2031 年的世界預測

本研究報告涵蓋了微小殘留疾病檢測市場的規模、佔有率、預測和趨勢分析：產品、技術（PCR、流式細胞儀、NGS）、應用（淋巴瘤、白血病、多發性骨髓瘤、實體瘤）、樣本（本是一份名為 "血液、骨髓）- 2031 年全球預測" 的新市場研究報告。至2031年，微小殘留疾病檢測市場預計將達到44.5億美元，2024-2031年預測期間複合年增長率為14.6%。

微小殘留疾病（MRD）檢測對於癌症患者極為重要。MRD 檢測可以早期瞭解接受治療的癌症患者是否有復發風險或癌症復發。早期資訊可以幫助醫生根據癌症類型和復發率做出治療決策，從而有可能改善患者的治療結果和生活品質。此外，MRD 檢測越來越多地被專注於開發癌症治療的製藥和生物製藥公司用於臨床試驗。這些是推動全球採用 MRD 檢測的一些關鍵因素。

微小殘留疾病檢測市場的成長也受到癌症盛行率的增加、MRD在血液惡性腫瘤中的應用增加、某些癌症的高復發率以及MRD檢測的投資和資金的增加所推動。此外，新興經濟體、腫瘤學領域擴大採用個人化治療和標靶治療，以及實體腫瘤病例中越來越多地使用 MRD 檢測，預計將為市場成長創造機會。

腫瘤學中擴大採用個人化和標靶治療

由於研究人員現在可以識別腫瘤特異性的基因譜，MRD 測試在個人化腫瘤醫學中正在取得進展。透過識別患者體內剩餘的癌細胞，醫生可以確定治療的強度，並根據個人對治療的反應調整治療。MRD檢測與個人化醫療密切相關，以提高治療效果，使病患管理更加精準。

將 MRD 測試納入臨床路徑可以驗證標靶治療。隨著針對特定基因突變的新藥被開發出來，MRD 檢測可以為治療效果提供有價值的見解。例如，2023年，美國FDA批准了16種罕見疾病的個人化治療方法，其中7種治療癌症。標靶治療和 MRD 檢測相結合有可能促進早期介入策略、預防復發並改善患者的長期結果。因此，腫瘤學領域向個人化和標靶治療的轉變預計將為 MRD（微小殘留疾病）檢測市場的參與者提供成長機會。

微小殘留疾病檢測市場的未來展望

在本報告調查的產品中，檢測和試劑部分預計將在 2024 年佔據微小殘留疾病檢測市場的最大佔有率，達到 76.7%。檢測方法和試劑的重複使用、腫瘤學領域的研究和開發的增加促使新的MRD 檢測的出現、市場參與者專注於引入用於微小殘留疾病檢測的新檢測方法、在臨床試驗中更多地採用MRD 檢測等都有助於並在這一領域佔據重要的市場佔有率。

在本報告研究的技術中，流式細胞儀領域預計到2024年將佔據微小殘留疾病檢測市場的最大佔有率，達到42.7%。該行業的巨大市場佔有率歸因於其能夠提供樣本中癌細胞數量和類型的即時定量數據、流式細胞儀的廣泛使用以及下一代測序（NGS）等先進技術。 ，流式細胞儀耗材的成本相對較低。

在本報告調查的應用中，預計到2024年血癌領域將在微小殘留疾病檢測市場中佔據很大佔有率。此細分市場的主要佔有率是由於血癌發病率的增加、新診斷技術的出現、對精準腫瘤學的日益關注、對血癌 MRD 檢測的高投資以及血癌 MRD 的影響。可用性。

在本報告研究的樣本類型中，預計到 2024 年，血液部分將佔據微小殘留疾病檢測市場的最大佔有率。由於癌症發病率不斷增加、採集血液樣本的非侵入性程序、定期基於血液的 MRD 監測提高患者依從性等，該細分市場是一個巨大的市場，佔據了市場佔有率。

在本報告研究的客戶類型中，預計到2024年，製藥和生物製藥領域將佔據微小殘留疾病檢測市場的最大佔有率。由於癌症治療藥物臨床試驗中MRD檢測的採用率較高、癌症治療藥物研發投入較高以及藥物臨床試驗中MRD檢測的推廣，該細分市場擁有較大的市場佔有率。 。

在本報告研究的地區中，預計亞太地區在預測期內的 2024 年複合年增長率最高。由於醫療保健基礎設施的改善，亞太地區對於醫療保健產品製造商和服務提供者來說是一個日益活躍的市場。亞太地區的人口成長是推動該地區醫療保健產業發展的關鍵因素。這種成長吸引了私人和公共機構投資開發 MRD 檢測解決方案。癌症發生率的上升、醫療保健基礎設施的改善、對個人化治療的日益關注、癌症篩檢舉措的增加以及癌症研究資金的可用性正在推動亞太地區的市場成長。

本報告調查的主要公司包括 Illumina, Inc.（美國）、Qiagen NV（荷蘭）、PerkinElmer, Inc.（美國）、F. Hoffmann-La Roche Ltd.（瑞士）和 Thermo Fisher Ltd.（瑞士） 。（美國）、Thermo Fisher Scientific, Inc.（瑞士）、Natera Inc.（美國）、Bio-Rad Laboratories, Inc.（美國）、Adaptive Biotechnologies Corporation（美國）、Sysmex Corporation（日本）、Integrated DNA Technologies, Inc . .（美國）、Twist Bioscience Corporation（美國）、Invivoscribe Inc.（美國）。

目錄

第1章 簡介

第2章 研究方法

第3章 執行摘要

第4章 市場洞察

  • 市場概況
  • 影響市場成長的因素
    • 促進因素
      • 癌症發生率增加
      • 增加對 MRD 檢測和研究的投資和資助
    • 阻礙因素
      • 微小殘留疾病檢測費用高
    • 機會
      • 腫瘤學中擴大採用個人化和標靶治療
      • 增加 MRD 檢測在實體腫瘤的應用
    • 任務
      • 誤報/漏報的可能性
    • 趨勢
      • 數位 PCR 的出現
      • 質譜法在 MRD 檢測的應用
      • 將單細胞多組學和人工智慧整合到微小殘留疾病檢測中
    • 因子分析
  • 監管分析
    • 北美
      • 美國
      • 加拿大
    • 歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
    • 拉丁美洲
    • 中東
  • 波特五力分析
  • 技術演進路線圖

第5章 微小殘留疾病檢測市場評估－透過提供

  • 概述
  • 測定和試劑
  • 檢驗設備
  • 軟件與服務

第6章 微小殘留疾病檢測市場評估－依技術分類

  • 概述
  • 流式細胞儀
  • 聚合酶鏈反應
  • 下一代定序儀
  • 其他技術

第7章 微小殘留疾病檢測市場評估－依應用

  • 概述
  • 血癌
    • 淋巴瘤
    • 白血病
      • 急性淋巴性白血病（ALL）
      • 慢性淋巴細胞白血病（CLL）
      • 其他白血病
    • 多發性骨髓瘤
    • 其他血癌
  • 實體腫瘤

第8章 微小殘留疾病檢測市場評估－依標本類型

  • 概述
  • 血
  • 骨髓
  • 其他樣品類型

第9章 微小殘留疾病檢測市場評估－依客戶類型

  • 概述
  • 製藥/生物製藥公司
  • 醫院
  • 診斷實驗室
  • 學術/研究機構/研究機構

第10章 微小殘留疾病檢測市場評估－分地區

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 瑞士
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東/非洲

第11章競爭格局

  • 概述
  • 主要成長策略
  • 競爭標桿
  • 比賽儀表板
    • 產業領導者
    • 市場差異化因素
    • 龍頭企業
    • 啟動
  • 市場佔有率分析（2023 年）
    • Natera Inc.（U.S.）
    • Bio-Rad Laboratories, Inc.（U.S.）
    • F. Hoffmann-La Roche Ltd.（Switzerland）
    • Adaptive Biotechnologies Corporation（U.S.）

第12章 公司簡介

  • Natera Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Adaptive Biotechnologies Corporation
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Qiagen N.V.
  • Integrated DNA Technologies, Inc.（U.S.）（A Subsidiary of Danaher Corporation[U.S.]）
  • Twist Bioscience Corporation
  • Sysmex Corporation
  • Invivoscribe, Inc.

第13章附錄

Product Code: MRHC - 1041385

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow)-Global Forecast to 2031

According to a new market research report titled, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis by Offering, Technology (PCR, Flow Cytometry, NGS), Application (Lymphoma, Leukemia, Multiple Myeloma, Solid Tumor), Sample (Blood, Bone Marrow)-Global Forecast to 2031' the minimal residual disease testing market is expected to reach $4.45 billion by 2031, at a CAGR of 14.6% during the forecast period 2024-2031.

Minimal Residual Disease (MRD) testing is crucial for cancer-affected patients. MRD tests provide early insights into whether a treated cancer patient is at risk of relapse or cancer recurrence. Early information helps physicians make treatment decisions depending on the cancer type and recurrence rates, which may lead to improved patient outcomes and better quality of life. Additionally, MRD testing is being increasingly used in clinical trials by pharmaceutical and biopharmaceutical companies focused on the development of cancer therapies. These are some of the major factors driving the adoption of MRD testing globally.

The growth of the minimal residual disease testing market is driven by the growing incidence of cancer, the increasing application of MRD in hematological malignancies, the high recurrence rates of some cancers, and increasing investments and funding for MRD testing. Moreover, emerging economies, the rising adoption of personalized treatments & targeted therapies in the field of oncology, and the growing use of MRD testing in cases of solid tumors are expected to generate market growth opportunities.

Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology

As researchers are able to identify the unique genetic profiles of tumors, MRD testing is gaining traction in personalized oncology medicine. By identifying residual cancer cells in a patient, physicians can make decisions about the intensity of the treatments or tailor treatments based on the individual's response to treatments. MRD testing goes hand in hand with personalized medicine to improve therapeutic efficacy and make patient management more precise.

The integration of MRD testing into clinical pathways supports the validation of targeted therapies. As new drugs are being developed to target specific genetic mutations, MRD testing can provide valuable insights into treatment effectiveness. For instance, in 2023, the U.S. FDA approved 16 personalized treatments for rare diseases, of which seven were for cancer. Combining targeted therapies and MRD testing can facilitate early intervention strategies, potentially preventing relapse and improving long-term outcomes for patients. Thus, the shift toward personalized treatments and targeted therapies in oncology is expected to generate growth opportunities for the players operating in the Minimal Residual Disease (MRD) testing market.

Minimal Residual Disease Testing Market: Future Outlook

The minimal residual disease testing market is segmented by Offering (Assays & Reagents, Instruments, and Software & Services), Technology (Flow Cytometry, Polymerase Chain Reaction [PCR], Next-generation Sequencing [NGS], and Other Technologies), Application (Blood Cancers [Lymphoma, Leukemia {Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, and Other Leukemias}, Multiple Myeloma, and Other Blood Cancers], and Solid Tumors), Sample Type (Blood, Bone Marrow, and Other Sample Types), Customer Type (Pharmaceutical & Biopharmaceutical Companies, Hospitals, Diagnostic Laboratories, and Academic & Research Organizations/Institutions), and Geography (North America [U.S. and Canada], Europe [Germany, France, U.K., Spain, Italy, Switzerland, Netherlands, and Rest of Europe], Asia-Pacific [China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific], Latin America [Brazil, Mexico, and Rest of Latin America], and the Middle East & Africa.

Among the offerings studied in this report, in 2024, the assays & reagents segment is expected to account for the largest share of 76.7% of the minimal residual disease testing market. The recurrent use of assays & reagents, increasing research & development in the field of oncology leading to the emergence of new MRD tests, market players' focus on introducing new assays for minimal residual disease testing, and the rising adoption of MRD testing in clinical trials, contribute to the substantial market share of this segment.

Among the technologies studied in this report, in 2024, the flow cytometry segment is expected to account for the largest share of 42.7% of the minimal residual disease testing market. This segment's significant market share is attributed to the technology's ability to provide real-time, quantitative data on the number and type of cancer cells in a sample, the widespread availability of flow cytometers, and the relatively lower costs of flow cytometry consumables compared to more advanced technologies such as Next-generation Sequencing (NGS).

Among the applications studied in this report, in 2024, the blood cancers segment is expected to account for the larger share of the minimal residual disease testing market. The segment's large share is attributed to the growing incidence of blood cancers, the advent of new diagnostic technologies, the rising focus on precision oncology, high investments in MRD testing for blood cancers, and the wide availability of MRD testing solutions for blood cancers.

Among the sample types studied in this report, in 2024, the blood segment is expected to account for the largest share of the minimal residual disease testing market. This segment holds a large market share due to the growing cancer incidence, the noninvasiveness of procedures used to obtain blood samples, and better patient compliance in the case of regular blood-based MRD monitoring.

Among the customer types studied in this report, in 2024, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the minimal residual disease testing market. This segment's large market share is attributed to the high adoption of MRD testing in clinical trials for oncology therapies, high investments in oncology drug development and research, and supportive initiatives by regulatory authorities to promote MRD testing in drug trials.

Among the geographies studied in this report, in 2024, APAC is estimated to register the highest CAGR during the forecast period. Asia-Pacific is becoming an increasingly active market for healthcare product manufacturers and service providers due to improving healthcare infrastructure in the region. Asia-Pacific's growing population is the key factor driving the region's healthcare sector. This growth is attracting investments from private and public organizations in the development of MRD testing solutions. The rising incidence of cancer, improving healthcare infrastructure, the growing focus on personalized therapies, increasing cancer screening initiatives, and the availability of funding for cancer research are driving market growth in Asia-Pacific.

Some of the major players studied in this report are Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Natera Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), Sysmex Corporation, (Japan), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), and Invivoscribe Inc. (U.S.).

Scope of the Report:

Minimal Residual Disease Testing Market Assessment-by Offering

Assays & Reagents

Instruments

Software & Services

Minimal Residual Disease Testing Market Assessment-by Technology

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-generation Sequencing (NGS)

Other Technologies

Minimal Residual Disease Testing Market Assessment-by Application

Blood Cancers

Lymphoma

Leukemia

Acute Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Other Leukemias

Multiple Myeloma

Other Blood Cancers

Solid Tumors

(Note: Other leukemias include chronic myeloid leukemia, B-cell prolymphocytic leukemia, and juvenile myelomonocytic leukemia.)

(Note: Other blood cancers include chronic myeloid leukemia, B-cell prolymphocytic leukemia, and juvenile myelomonocytic leukemia.)

Minimal Residual Disease Testing Market Assessment-by Sample Type

Blood

Bone Marrow

Other Sample Types

Minimal Residual Disease Testing Market Assessment-by Customer Type

Pharmaceutical & Biopharmaceutical Companies

Hospitals

Diagnostic Laboratories

Academic & Research Organizations/Institutions

Minimal Residual Disease Testing Market Assessment-by Geography

North America

U.S.

Canada

Europe

U.K.

Germany

France

Italy

Spain

Switzerland

Netherlands

Rest of Europe

Asia-Pacific

China

Japan

India

Australia

South Korea

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency & Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Growing Incidence of Cancer
      • 4.2.1.2. Increasing Investments & Funding for MRD Testing & Research
    • 4.2.2. Restraints
      • 4.2.2.1. High Costs of Minimal Residual Disease Testing
    • 4.2.3. Opportunities
      • 4.2.3.1. Rising Adoption of Personalized Treatments & Targeted Therapies In the Field of Oncology
      • 4.2.3.2. Growing Use of MRD Testing In Cases of Solid Tumors
    • 4.2.4. Challenges
      • 4.2.4.1. Chances of False Positive/Negative Results
    • 4.2.5. Trends
      • 4.2.5.1. Emergence of Digital PCR
      • 4.2.5.2. Use of Mass Spectrometry for MRD Testing
      • 4.2.5.3. Integration of Single-Cell Multiomics & Artificial Intelligence Into Minimal Residual Disease Testing
    • 4.2.6. Factors Analysis
  • 4.3. Regulatory Analysis
    • 4.3.1. North America
      • 4.3.1.1. U.S.
      • 4.3.1.2. Canada
    • 4.3.2. Europe
    • 4.3.3. Asia-Pacific
      • 4.3.3.1. China
      • 4.3.3.2. Japan
      • 4.3.3.3. India
    • 4.3.4. Latin America
    • 4.3.5. Middle East
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Buyers
    • 4.4.2. Bargaining Power of Suppliers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Technology Evolution Roadmap

5. Minimal Residual Disease Testing Market Assessment- By Offering

  • 5.1. Overview
  • 5.2. Assays & Reagents
  • 5.3. Instruments
  • 5.4. Software & Services

6. Minimal Residual Disease Testing Market Assessment- By Technology

  • 6.1. Overview
  • 6.2. Flow Cytometry
  • 6.3. Polymerase Chain Reaction
  • 6.4. Next-Generation Sequencing
  • 6.5. Other Technologies

7. Minimal Residual Disease Testing Market Assessment- By Application

  • 7.1. Overview
  • 7.2. Blood Cancers
    • 7.2.1. Lymphoma
    • 7.2.2. Leukemia
      • 7.2.2.1. Acute Lymphoblastic Leukemia (ALL)
      • 7.2.2.2. Chronic Lymphocytic Leukemia (CLL)
      • 7.2.2.3. Other Leukemias
    • 7.2.3. Multiple Myeloma
    • 7.2.4. Other Blood Cancers
  • 7.3. Solid Tumors

8. Minimal Residual Disease Testing Market Assessment- By Sample Type

  • 8.1. Overview
  • 8.2. Blood
  • 8.3. Bone Marrow
  • 8.4. Other Sample Types

9. Minimal Residual Disease Testing Market Assessment- By Customer Type

  • 9.1. Overview
  • 9.2. Pharmaceutical & Biopharmaceutical Companies
  • 9.3. Hospitals
  • 9.4. Diagnostic Laboratories
  • 9.5. Academic & Research Organizations/Institutions

10. Minimal Residual Disease Testing Market Assessment- By Geography

  • 10.1. Overview
  • 10.2. North America
    • 10.2.1. U.S.
    • 10.2.2. Canada
  • 10.3. Europe
    • 10.3.1. Germany
    • 10.3.2. U.K.
    • 10.3.3. France
    • 10.3.4. Italy
    • 10.3.5. Spain
    • 10.3.6. Switzerland
    • 10.3.7. Netherlands
    • 10.3.8. Rest of Europe
  • 10.4. Asia-Pacific
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. South Korea
    • 10.4.5. Australia
    • 10.4.6. Rest of Asia-Pacific
  • 10.5. Latin America
    • 10.5.1. Brazil
    • 10.5.2. Mexico
    • 10.5.3. Rest of Latin America
  • 10.6. Middle East & Africa

11. Competitive Landscape

  • 11.1. Overview
  • 11.2. Key Growth Strategies
  • 11.3. Competitive Benchmarking
  • 11.4. Competitive Dashboard
    • 11.4.1. Industry Leaders
    • 11.4.2. Market Differentiators
    • 11.4.3. Vanguards
    • 11.4.4. Emerging Companies
  • 11.5. Market Share Analysis (2023)
    • 11.5.1. Natera Inc. (U.S.)
    • 11.5.2. Bio-Rad Laboratories, Inc. (U.S.)
    • 11.5.3. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 11.5.4. Adaptive Biotechnologies Corporation (U.S.)

12. Company Profiles

  • 12.1. Natera Inc.
  • 12.2. Bio-Rad Laboratories, Inc.
  • 12.3. F. Hoffmann-La Roche Ltd.
  • 12.4. Adaptive Biotechnologies Corporation
  • 12.5. Illumina, Inc.
  • 12.6. Thermo Fisher Scientific, Inc.
  • 12.7. Qiagen N.V.
  • 12.8. Integrated DNA Technologies, Inc. (U.S.) (A Subsidiary of Danaher Corporation [U.S.])
  • 12.9. Twist Bioscience Corporation
  • 12.10. Sysmex Corporation
  • 12.11. Invivoscribe, Inc.

13. Appendix

  • 13.1. Available Customization
  • 13.2. Related Reports

LIST OF TABLES

  • Table 1 Global Estimated Number of New Cancer Cases, By Type, 2020 Vs. 2030
  • Table 2 Cancer Recurrence Rates, By Cancer Type
  • Table 3 FDA-Approved Personalized Therapies for Cancer, 2019-2023
  • Table 4 Regulatory Authorities Governing IVD, Flow Cytometry, PCR, and NGS Products, By Country/Region
  • Table 5 Global Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 6 Key Market Players' Assay & Reagent Offerings
  • Table 7 Global Minimal Residual Disease Testing Assays & Reagents Market, By Country/Region, 2022-2031 (USD Million)
  • Table 8 Key Market Players' Instrument Offerings
  • Table 9 Global Minimal Residual Disease Testing Instruments Market, By Country/Region, 2022-2031 (USD Million)
  • Table 10 Key Market Players' Software Offerings
  • Table 11 Global Minimal Residual Disease Testing Software & Services Market, By Country/Region, 2022-2031 (USD Million)
  • Table 12 MRD Testing Technologies: Overview
  • Table 13 Global Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 14 Global Flow Cytometry-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 15 Global PCR-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 16 Global NGS-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Other Technologies-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million) 90
  • Table 19 Global Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 20 Global Minimal Residual Disease Testing Market for Blood Cancers, By Country/Region, 2022-2031 (USD Million) 92
  • Table 21 Estimated Number of New Lymphoma Cases, By Region, 2022 Vs. 2025 Vs. 2030 (Thousand)
  • Table 22 Survival Rates for Diffuse Large B-Cell Lymphoma, By Seer Stage (%)
  • Table 23 Survival Rates for Follicular Lymphoma, By Seer Stage (%)
  • Table 24 Reoccurrence Rates In Lymphoma-Affected Patients, By Condition (%)
  • Table 25 Global Minimal Residual Disease Testing Market for Lymphoma, By Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 27 Global Minimal Residual Disease Testing Market for Leukemia, By Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Minimal Residual Disease Testing Market for Acute Lymphoblastic Leukemia, By Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Minimal Residual Disease Testing Market for Chronic Lymphocytic Leukemia, By Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Minimal Residual Disease Testing Market for Other Leukemias, By Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Minimal Residual Disease Testing Market for Multiple Myeloma, By Country/Region, 2022-2031 (USD Million)
  • Table 32 Types of Myelodysplastic Syndromes
  • Table 33 Types of Myeloproliferative Neoplasms
  • Table 34 Global Minimal Residual Disease Testing Market for Other Blood Cancers, By Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Estimated Number of New Cancer Cases, By Type, 2020 Vs. 2030
  • Table 36 Global Minimal Residual Disease Testing Market for Solid Tumors, By Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 38 Global Blood-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 39 Global Bone Marrow-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 40 Global Other Samples-Based Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 41 Global Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 42 Global Minimal Residual Disease Testing Market for Pharmaceutical & Biopharmaceutical Companies, By Country/Region, 2022-2031 (USD Million)
  • Table 43 Global Minimal Residual Disease Testing Market for Hospitals, By Country/Region, 2022-2031 (USD Million)
  • Table 44 Global Minimal Residual Disease Testing Market for Diagnostic Laboratories, By Country/Region, 2022-2031 (USD Million)
  • Table 45 Global Minimal Residual Disease Testing Market for Academic & Research Organizations/Institutions, By Country/Region, 2022-2031 (USD Million)
  • Table 46 Global Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 47 North America: Minimal Residual Disease Testing Market, By Country, 2022-2031 (USD Million)
  • Table 48 North America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 49 North America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 50 North America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 51 North America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 52 North America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 53 North America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 54 North America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 55 U.S.: Estimated Number of New Cancer Cases By Type & State, 2024
  • Table 56 U.S.: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 57 U.S.: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 58 U.S.: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 59 U.S.: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 60 U.S.: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 61 U.S.: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 62 U.S.: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 63 Canada: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 64 Canada: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 65 Canada: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 66 Canada: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 67 Canada: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 68 Canada: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 69 Canada: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 70 Europe: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 71 Europe: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 72 Europe: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 73 Europe: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 74 Europe: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 75 Europe: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 76 Europe: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 77 Europe: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 78 Germany: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 79 Germany: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 80 Germany: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 81 Germany: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 82 Germany: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 83 Germany: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 84 Germany: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 85 U.K.: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 86 U.K.: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 87 U.K.: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 88 U.K.: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 89 U.K.: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 90 U.K.: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 91 U.K.: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 92 France: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 93 France: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 94 France: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 95 France: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 96 France: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 97 France: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 98 France: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 99 Italy: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 100 Italy: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 101 Italy: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 102 Italy: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 103 Italy: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 104 Italy: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 105 Italy: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 106 Spain: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 107 Spain: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 108 Spain: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 109 Spain: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 110 Spain: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 111 Spain: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 112 Spain: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 113 Switzerland: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 114 Switzerland: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 115 Switzerland: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 116 Switzerland: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 117 Switzerland: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 118 Switzerland: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 119 Switzerland: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 120 Netherlands: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 121 Netherlands: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 122 Netherlands: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 123 Netherlands: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 124 Netherlands: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 125 Netherlands: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 126 Netherlands: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 127 Rest of Europe: Number of New Cancer Cases, By Country, 2022 Vs. 2030
  • Table 128 Rest of Europe: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 129 Rest of Europe: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 130 Rest of Europe: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 131 Rest of Europe: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 132 Rest of Europe: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 133 Rest of Europe: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 134 Rest of Europe: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 135 Asia-Pacific: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 136 Asia-Pacific: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 137 Asia-Pacific: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 138 Asia-Pacific: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 139 Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 140 Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 141 Asia-Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 142 Asia-Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 143 China: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 144 China: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 145 China: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 146 China: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 147 China: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 148 China: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 149 China: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 150 Japan: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 151 Japan: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 152 Japan: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 153 Japan: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 154 Japan: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 155 Japan: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 156 Japan: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 157 India: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 158 India: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 159 India: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 160 India: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 161 India: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 162 India: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 163 India: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 164 South Korea: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 165 South Korea: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 166 South Korea: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 167 South Korea: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 168 South Korea: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 169 South Korea: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 170 South Korea: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 171 Australia: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 172 Australia: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 173 Australia: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 174 Australia: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 175 Australia: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 176 Australia: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 177 Australia: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 178 Rest of Asia-Pacific: Number of New Cancer Cases, By Country, 2022 Vs. 2030
  • Table 179 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 180 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 181 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 182 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 183 Rest of Asia-Pacific: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 184 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 185 Rest of Asia-Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 186 Latin America: Minimal Residual Disease Testing Market, By Country/Region, 2022-2031 (USD Million)
  • Table 187 Latin America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 188 Latin America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 189 Latin America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 190 Latin America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 191 Latin America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 192 Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 193 Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 194 Brazil: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 195 Brazil: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 196 Brazil: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 197 Brazil: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 198 Brazil: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 199 Brazil: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 200 Brazil: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 201 Mexico: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 202 Mexico: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 203 Mexico: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 204 Mexico: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 205 Mexico: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 206 Mexico: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 207 Mexico: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 208 Rest of Latin America: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 209 Rest of Latin America: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 210 Rest of Latin America: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 211 Rest of Latin America: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 212 Rest of Latin America: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 213 Rest of Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 214 Rest of Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 215 Middle East & Africa: Minimal Residual Disease Testing Market, By Offering, 2022-2031 (USD Million)
  • Table 216 Middle East & Africa: Minimal Residual Disease Testing Market, By Technology, 2022-2031 (USD Million)
  • Table 217 Middle East & Africa: Minimal Residual Disease Testing Market, By Application, 2022-2031 (USD Million)
  • Table 218 Middle East & Africa: Minimal Residual Disease Testing Market for Blood Cancers, By Type, 2022-2031 (USD Million)
  • Table 219 Middle East & Africa: Minimal Residual Disease Testing Market for Leukemia, By Type, 2022-2031 (USD Million)
  • Table 220 Middle East & Africa: Minimal Residual Disease Testing Market, By Sample Type, 2022-2031 (USD Million)
  • Table 221 Middle East & Africa: Minimal Residual Disease Testing Market, By Customer Type, 2022-2031 (USD Million)
  • Table 222 Recent Developments, By Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Market Ecosystem
  • Figure 2 Research Process
  • Figure 3 Secondary Sources Referenced for This Study
  • Figure 4 Primary Research Techniques
  • Figure 5 Key Executives Interviewed
  • Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 7 Market Sizing & Growth Forecast Approach
  • Figure 8 Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)
  • Figure 9 Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)
  • Figure 10 Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 11 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)
  • Figure 12 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
  • Figure 13 Global Minimal Residual Disease Testing Market, By Geography
  • Figure 14 Impact Analysis of Market Dynamics
  • Figure 15 USFDA Regulatory Pathways for IVD Products
  • Figure 16 Eu Regulatory Pathway - IVDR 2017/746
  • Figure 17 China: Medical Device Classification and Pre-Market Requirements for MRD Testing Instruments
  • Figure 18 Saudi Arabia: Medical Device - Marketing Authorization Process
  • Figure 19 Porter's Five Forces Analysis
  • Figure 20 Minimal Residual Disease Testing: Technology Evolution Roadmap
  • Figure 21 Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)
  • Figure 22 Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)
  • Figure 23 Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)
  • Figure 24 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)
  • Figure 25 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
  • Figure 26 Global Minimal Residual Disease Testing Market, By Geography, 2024 Vs. 2031 (USD Million)
  • Figure 27 North America: Minimal Residual Disease Testing Market Snapshot
  • Figure 28 Europe: Minimal Residual Disease Testing Market Snapshot
  • Figure 29 U.K.: Number of New Cancer Cases, 2022-2040
  • Figure 30 France: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
  • Figure 31 Switzerland: Number of New Cancer Cases, 2022-2040
  • Figure 32 Netherlands: Number of New Cancer Cases, 2022-2040
  • Figure 33 Asia-Pacific: Minimal Residual Disease Testing Market Snapshot
  • Figure 34 South Korea: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
  • Figure 35 Latin America: Minimal Residual Disease Testing Market Snapshot
  • Figure 36 Mexico: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
  • Figure 37 Middle East & Africa: Number of New Cancer Cases, By Country, 2022 Vs. 2030
  • Figure 38 Key Growth Strategies Adopted By Leading Players, 2021-2024
  • Figure 39 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Technology
  • Figure 40 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Region
  • Figure 41 Competitive Dashboard: Minimal Residual Disease Testing Market
  • Figure 42 Global Minimal Residual Disease Testing Market Share Analysis, By Key Players (2023)
  • Figure 43 Natera Inc.: Financial Overview (2023)
  • Figure 44 Bio-Rad Laboratories, Inc.: Financial Overview (2023)
  • Figure 45 F. Hoffmann-La Roche Ltd.: Financial Overview (2023)
  • Figure 46 Adaptive Biotechnologies Corporation.: Financial Overview (2023)
  • Figure 47 Illumina Inc.: Financial Overview (2023)
  • Figure 48 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
  • Figure 49 Qiagen N.V.: Financial Overview (2023)
  • Figure 50 Danaher Corporation: Financial Overview (2023)
  • Figure 51 Twist Bioscience Corporation: Financial Overview (2023)
  • Figure 52 Sysmex Corporation: Financial Overview (2024)